Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by Amalgamated Bank

Amalgamated Bank lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,373 shares of the biopharmaceutical company’s stock after selling 2,447 shares during the period. Amalgamated Bank’s holdings in Regeneron Pharmaceuticals were worth $14,512,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FourThought Financial Partners LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $435,000. Pine Valley Investments Ltd Liability Co boosted its position in Regeneron Pharmaceuticals by 24.7% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 6,612 shares of the biopharmaceutical company’s stock valued at $4,710,000 after purchasing an additional 1,309 shares during the period. IFP Advisors Inc grew its position in shares of Regeneron Pharmaceuticals by 17.2% during the fourth quarter. IFP Advisors Inc now owns 368 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 54 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in Regeneron Pharmaceuticals by 22.3% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 11,525 shares of the biopharmaceutical company’s stock worth $8,210,000 after purchasing an additional 2,100 shares during the last quarter. Finally, Forvis Mazars Wealth Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.3% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 3,255 shares of the biopharmaceutical company’s stock valued at $2,319,000 after purchasing an additional 41 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Bank of America reissued an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Up 1.4 %

Shares of REGN opened at $723.47 on Wednesday. The business’s 50-day moving average price is $698.84 and its 200 day moving average price is $875.48. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $79.09 billion, a P/E ratio of 18.90, a P/E/G ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $11.86 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.